Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advanced Life Sciences Holdings has announced that, based on a productive meeting with the FDA, the company plans to submit a new drug application in the third quarter of 2008 for its once-a-day oral antibiotic, cethromycin, to treat mild-to-moderate community acquired pneumonia.
Subscribe to our email newsletter
The FDA will review any submission the company makes to determine whether it meets the requirements for filing. There can be no assurance that the FDA will file the NDA, or that once filed, it will be approved.
Michael Flavin, CEO of Advanced Life Sciences, said: “We are pleased with the outcome of the meeting because it allows us to remain on track with our NDA submission goal. In addition, we believe that achieving this milestone will enable our partnership discussions to continue toward a conclusion in a timely manner.”